简报:司库奇尤单抗阻断白细胞介素-17对外周脊柱关节炎滑膜免疫病理的调节作用及对全身免疫反应的影响
这项12周开放标签试验纳入20例外周脊柱关节炎患者,给予司库奇尤单抗300 mg(基线至第4周每周一次,之后每4周一次)。20例中13例达到ACR20,关节计数改善与滑膜衬里下层巨噬细胞和中性粒细胞减少及IL-17A mRNA表达下降相关,全身细胞因子产生能力除IL-17A外未受影响。
要点
- 20例外周脊柱关节炎患者中13例在第12周达到ACR20,其中8例达ACR50、5例达ACR70。
- 关节计数改善与滑膜衬里下层巨噬细胞(P=0.028)和中性粒细胞(P=0.004)减少相关。
- 除IL-17A本身外,外周血细胞对微生物抗原刺激产生多种细胞因子的能力未受影响。
核心结论
- 在外周脊柱关节炎中,司库奇尤单抗治疗的临床改善伴随炎症靶组织的免疫调节,而全身免疫反应未受损。
研究设计与样本
- 12周开放标签试验,纳入20例活动性外周脊柱关节炎患者,司库奇尤单抗300 mg从基线至第4周每周一次、之后每4周一次。
主要发现
- 所有患者完成12周研究,无严重不良事件或严重治疗相关不良事件。
- 20例中13例在第12周达到ACR20,其中8例达到ACR50、5例达到ACR70,所有临床疾病活动度指标快速且显著改善。
- 关节计数临床改善与滑膜衬里下层巨噬细胞减少(P=0.028)、中性粒细胞减少(P=0.004)以及滑膜IL-17A信使RNA表达下降(P=0.010)相关,而与肿瘤坏死因子mRNA无关。
- 司库奇尤单抗治疗降低了C反应蛋白水平和红细胞沉降率(均P<0.01),并降低了TruCulture系统中基质金属蛋白酶3的产生(P<0.05)。
- 除IL-17A本身外,外周血细胞在微生物抗原刺激下产生广谱细胞因子和趋化因子的能力未受影响。
关键数值与推荐
- 疗效终点为第12周达到美国风湿病学会20%改善标准(ACR20)的患者数,20例中13例达到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Secukinumab (anti-interleukin-17A [anti-IL-17A]) is an effective therapy for ankylosing spondylitis and psoriatic arthritis, the prototypical forms of spondyloarthritis (SpA). We undertook this study to determine whether secukinumab modulates the immunopathology of target lesions without blunting systemic immune responses, using peripheral SpA as a model. METHODS: Twenty patients with active peripheral SpA were included in a 12-week open-label trial with secukinumab (300 mg once weekly from baseline to week 4 and then every 4 weeks thereafter). Outcomes included clinical response, cytokine production by peripheral blood cells using TruCulture technology, and histologic and real-time quantitative polymerase chain reaction analysis of synovial biopsy samples before and after treatment. RESULTS: All patients completed the 12-week study without severe adverse events (AEs) or severe treatment-related AEs. The efficacy end point, the number of patients meeting the American College of Rheumatology 20% improvement criteria (achieving an ACR20 response) at 12 weeks, was achieved by 13 of the 20 patients, of whom 8 achieved an ACR50 response and 5 achieved an ACR70 response, with rapid and significant improvements in all clinical disease activity measures. Clinical improvement in joint counts was associated with a histologic decrease in synovial sublining macrophages (P = 0.028) and neutrophils (P = 0.004), both of which are sensitive synovial biomarkers of inflammatory response in peripheral SpA, as well as with decreased synovial expression of IL-17A messenger RNA (mRNA) (P = 0.010) but not of tumor necrosis factor mRNA. Systemically, secukinumab treatment decreased the C-reactive protein level and the erythrocyte sedimentation rate (both P < 0.01), and also decreased matrix metalloproteinase 3 production in the TruCulture system (P < 0.05). However, with the exception of IL-17A itself, the capacity of peripheral blood cells to produce a broad panel of cytokines and chemokines upon stimulation with microbial antigens was not affected. CONCLUSION: This mechanism-of-action study in peripheral SpA indicates that clinical improvement with secukinumab treatment is paralleled by immunomodulation of inflamed target tissues without compromising systemic immune responses.
引用
- van Mens LJJ, van de Sande MGH, Menegatti S, et al. Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses. Arthritis Rheumatol. 2018. PMID: 29869838. doi:10.1002/art.40581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。